Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Universal American Corporation UAM NYSE

NYSE • Healthcare • Medical - Healthcare Plans • USD

SharesGrow Score
40/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Universal American Corporation (UAM) is a Medical - Healthcare Plans company in the Healthcare sector, currently trading at $1.75. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $1.4B, -13.3%/yr average growth. Net income is $55M, growing at -79.3%/yr. Net profit margin is 4% (thin). Gross margin is 16.4% (-6.8 pp trend).

Balance sheet: total debt is $186M against $269M equity (Debt-to-Equity (D/E) ratio 0.69, moderate). Current ratio is 2.31 (strong liquidity). Debt-to-assets is 23.7%. Total assets: $786M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 50/100 (Partial), Moat 19/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

UAM SharesGrow Score Overview

40/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 19/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — UAM

✓
VALUE Pass
100/100
UAM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
UAM: -13.3%/yr revenue is, -79.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
UAM: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet UAM: Debt-to-Equity (D/E) ratio 0.69 (moderate), Current ratio is 2.31 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
19/100
UAM: Gross margin is 16.4% (-6.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 19/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
30/100
UAM: Net profit margin is 4%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.85-1.6
Avg Volume (30D)913
Beta (1Y)-0.46
Share Statistics
EPS (TTM)0.78
Shares Outstanding$70.67M
IPO Date2019-04-15
Financial Highlights & Ratios
Revenue (TTM)$1.38B
Gross Profit$225.82M
EBITDA$77.65M
Net Income$55.38M
Operating Income$-1.94M
Total Cash$355.96M
Total Debt$185.79M
Net Debt$81.33M
Total Assets$785.58M
Price / Earnings (P/E)2.2
Analyst Forecast
Company Info
ExchangeNYSE
CurrencyUSD

Price Chart

Track all markets on TradingView
UAM
Universal American Corporation  ·  NYSE
Healthcare • Medical - Healthcare Plans

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message